Search results
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via Yahoo Finance· 14 hours agoMonday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and...
Why Merck & Co Inc (NYSE: MRK) Is A Stock Not To Be Discarded In 2024 – Marketing Sentinel
Marketing Sentinel· 24 hours agoIn today’s recent session, 2.33 million shares of the Merck & Co Inc (NYSE:MRK) have been traded, and its beta is 0.42. Most recently the company’s share price was $128.25 ...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 14 hours agoMerck announced Monday that it is pulling the plug on its phase 3 trial of an experimental...
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
Simply Wall St. via Yahoo Finance· 4 days agoBy buying an index fund, investors can approximate the average market return. But if you pick the...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 20 hours agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck Expands Access to High-Quality Maternal Care for More
3BL CSRwire· 19 hours agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health initiative ...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 19 hours ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 18 hours agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Market Watch· 19 hours agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-cancer patients because the study was likely to ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 27 minutes agoOSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration
